Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo

[1]  D. Ribatti,et al.  Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model , 2011, Leukemia.

[2]  G. Lenz,et al.  Pathogenesis of non-Hodgkin's lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Morandi,et al.  Interleukin‐27 and interleukin‐23 modulate human plasmacell functions , 2011, Journal of leukocyte biology.

[4]  Guobin Wang,et al.  Th17 cells in cancer: help or hindrance? , 2011, Carcinogenesis.

[5]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[6]  R. Gascoyne,et al.  Vascularization predicts overall survival and risk of transformation in follicular lymphoma , 2010, Haematologica.

[7]  J. Vose,et al.  A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma , 2010, British Journal of Cancer.

[8]  D. Ribatti,et al.  Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. , 2010, Blood.

[9]  R. Gascoyne,et al.  Prognostic factors in follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Zupo,et al.  Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. , 2010, Experimental hematology.

[11]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[12]  S. Paydaş.  Anti-angiogenic strategies will be a revolution in lymphoma? , 2010, Leukemia research.

[13]  I. Lossos,et al.  Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. , 2010, Blood.

[14]  R. Mohammad,et al.  New targets for the treatment of follicular lymphoma , 2009, Journal of hematology & oncology.

[15]  M. Banerjee,et al.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. , 2009, Blood.

[16]  R. D. Hatton,et al.  Developmental plasticity of Th17 and Treg cells. , 2009, Current opinion in immunology.

[17]  Ganguly Siddhartha,et al.  R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature , 2009, Journal of hematology & oncology.

[18]  F. B. Sørensen,et al.  Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas , 2009, Leukemia & lymphoma.

[19]  D. Ribatti,et al.  Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. , 2008, Blood.

[20]  B. Aggarwal,et al.  Targeting Nuclear Factor-κB Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis , 2008, Molecular Cancer Research.

[21]  H. Nagai,et al.  Antiproliferative Activity of IL-27 on Melanoma1 , 2008, The Journal of Immunology.

[22]  K. Ganjoo,et al.  The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients , 2008, Journal of Cancer Research and Clinical Oncology.

[23]  Dajun Yang,et al.  Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model , 2008, Molecular Cancer.

[24]  K. Makabe,et al.  High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. , 2007, Cancer letters.

[25]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Ribatti,et al.  Endogenous IL-12 triggers an antiangiogenic program in melanoma cells , 2007, Proceedings of the National Academy of Sciences.

[28]  F. B. Sørensen,et al.  Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes , 2007, Leukemia & lymphoma.

[29]  O. Bairey,et al.  Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas , 2007, Leukemia & lymphoma.

[30]  M. Caligiuri,et al.  A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[31]  S. Miyakis,et al.  Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. , 2006, European journal of internal medicine.

[32]  D. Farkas,et al.  Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. , 2006, Cancer research.

[33]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[34]  M. Kudo,et al.  Antiangiogenic and Antitumor Activities of IL-271 , 2006, The Journal of Immunology.

[35]  H. Nagai,et al.  Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. , 2006, Cancer research.

[36]  R. Kastelein,et al.  Differential Effects of IL-27 on Human B Cell Subsets1 , 2006, The Journal of Immunology.

[37]  M. Tagawa,et al.  Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. , 2006, Cellular & molecular immunology.

[38]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[39]  I. Flinn,et al.  Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease , 2004, Clinical Cancer Research.

[40]  A. Amadori,et al.  The IL-12Rβ2 gene functions as a tumor suppressor in human B cell malignancies , 2004 .

[41]  T. Mcclanahan,et al.  WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27 , 2004, The Journal of Immunology.

[42]  Maria Laura Belladonna,et al.  Potent Antitumor Activity of Interleukin-27 , 2004, Cancer Research.

[43]  G. Trinchieri,et al.  The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. , 2003, Immunity.

[44]  Cheng-Wen Wu,et al.  Antitumor and Antimetastatic Activity of IL-231 , 2003, The Journal of Immunology.

[45]  T. Mcclanahan,et al.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. , 2002, Immunity.

[46]  T. Mcclanahan,et al.  A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.

[47]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[48]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[49]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A Vacca,et al.  New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. , 1997, Journal of vascular research.

[51]  M. Andreeff,et al.  A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. , 1996, Blood.

[52]  R. Kurzrock,et al.  Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. Mohammad,et al.  A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). , 1993, Cancer genetics and cytogenetics.

[54]  T. Lister,et al.  Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. , 1993, Blood.

[55]  C. Gisselbrecht,et al.  Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. , 1992, Blood.

[56]  Elaine S. Jaffe,et al.  evolving concepts and practical applications The 2008 WHO classification of lymphoid neoplasms and beyond , 2011 .

[57]  Pierre Biron,et al.  Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival , 2009, Annals of Hematology.

[58]  R. Tibshirani,et al.  Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy , 2008, Laboratory Investigation.

[59]  J. Raemaekers,et al.  Increased vascularization predicts favorable outcome in follicular lymphoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.